Suppr超能文献

经壁协作护理与咨询信(TCCCL)及度洛西汀联合初级保健治疗重度抑郁症(MDD)和(亚)慢性疼痛的有效性和成本效益:一项随机安慰剂对照多中心试验的设计:TCC:PAINDIP

Effectiveness and cost-effectiveness of transmural collaborative care with consultation letter (TCCCL) and duloxetine for major depressive disorder (MDD) and (sub)chronic pain in collaboration with primary care: design of a randomized placebo-controlled multi-Centre trial: TCC:PAINDIP.

作者信息

de Heer Eric W, Dekker Jack, van Eck van der Sluijs Jonna F, Beekman Aartjan Tf, van Marwijk Harm Wj, Holwerda Tjalling J, Bet Pierre M, Roth Joost, Hakkaart-Van Roijen Leona, Ringoir Lianne, Kat Fiona, van der Feltz-Cornelis Christina M

出版信息

BMC Psychiatry. 2013 May 24;13:147. doi: 10.1186/1471-244X-13-147.

Abstract

BACKGROUND

The comorbidity of pain and depression is associated with high disease burden for patients in terms of disability, wellbeing, and use of medical care. Patients with major and minor depression often present themselves with pain to a general practitioner and recognition of depression in such cases is low, but evolving. Also, physical symptoms, including pain, in major depressive disorder, predict a poorer response to treatment. A multi-faceted, patient-tailored treatment programme, like collaborative care, is promising. However, treatment of chronic pain conditions in depressive patients has, so far, received limited attention in research. Cost effectiveness of an integrated approach of pain in depressed patients has not been studied.

METHODS/DESIGN: This study is a placebo controlled double blind, three armed randomized multi centre trial. Patients with (sub)chronic pain and a depressive disorder are randomized to either a) collaborative care with duloxetine, b) collaborative care with placebo or c) duloxetine alone. 189 completers are needed to attain sufficient power to show a clinically significant effect of 0.6 SD on the primary outcome measures (PHQ-9 score). Data on depression, anxiety, mental and physical health, medication adherence, medication tolerability, quality of life, patient-doctor relationship, coping, health resource use and productivity will be collected at baseline and after three, six, nine and twelve months.

DISCUSSION

This study enables us to show the value of a closely monitored integrated treatment model above usual pharmacological treatment. Furthermore, a comparison with a placebo arm enables us to evaluate effectiveness of duloxetine in this population in a real life setting. Also, this study will provide evidence-based treatments and tools for their implementation in practice. This will facilitate generalization and implementation of results of this study. Moreover, patients included in this study are screened for pain symptoms, differentiating between nociceptive and neuropathic pain. Therefore, pain relief can be thoroughly evaluated.

TRIAL REGISTRATION

NTR1089.

摘要

背景

疼痛与抑郁的共病在残疾、健康状况及医疗护理使用方面给患者带来了沉重的疾病负担。患有重度和轻度抑郁症的患者常因疼痛前往全科医生处就诊,在此类情况下对抑郁症的识别率较低,但正在逐步提高。此外,重度抑郁症中的身体症状,包括疼痛,预示着对治疗的反应较差。像协作式照护这样多方面、针对患者量身定制的治疗方案很有前景。然而,迄今为止,抑郁患者慢性疼痛病症的治疗在研究中受到的关注有限。尚未对抑郁症患者疼痛综合治疗方法的成本效益进行研究。

方法/设计:本研究是一项安慰剂对照双盲、三臂随机多中心试验。患有(亚)慢性疼痛和抑郁症的患者被随机分为:a)度洛西汀协作式照护组,b)安慰剂协作式照护组,或c)单独使用度洛西汀组。需要189名完成者才能获得足够的效力,以显示在主要结局指标(PHQ - 9评分)上有0.6标准差的临床显著效果。将在基线以及3个月、6个月、9个月和12个月后收集有关抑郁、焦虑、心理和身体健康、药物依从性、药物耐受性、生活质量、医患关系、应对方式、卫生资源使用和生产力的数据。

讨论

本研究使我们能够证明密切监测的综合治疗模式优于常规药物治疗的价值。此外,与安慰剂组的比较使我们能够在现实生活环境中评估度洛西汀在此类人群中的有效性。而且,本研究将为循证治疗及其在实践中的实施提供工具。这将促进本研究结果的推广和实施。此外,本研究纳入的患者会接受疼痛症状筛查,区分伤害性疼痛和神经性疼痛。因此,可以对疼痛缓解情况进行全面评估。

试验注册

NTR1089

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/240c/3698098/80d31c398896/1471-244X-13-147-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验